Effect of multiple intravenous injections of butaphosphan and cyanocobalamin on the metabolism of periparturient dairy cows.
Numerous adjunct therapeutic agents have been investigated for the treatment or control of fat mobilization syndrome in periparturient dairy cows. The aim of this study was to determine the effects of multiple i.v. injections of 10% butaphosphan and 0.005% cyanocobalamin combination (Catosal, Bayer Animal Health, Leverkusen, Germany) between 1 and 2 wk antepartum (a.p.) on the metabolism and health of dairy cows. Forty-five late-gestation Holstein-Friesian cows (second pregnancy) were allocated randomly to 1 of 3 groups with 15 cows/group: group C6 (6 daily i.v. injections of butaphosphan at 10 mg/kg of body weight (BW) and cyanocobalamin at 5 microg/kg of BW in the last 2 wk of gestation); group C3 (3 daily i.v. injections of butaphosphan at 10 mg/kg of BW and cyanocobalamin at 5 microg/kg of BW in the last week of gestation); and group C0 (equivolume daily i.v. injections of 0.9% NaCl solution). Serum biochemical analysis was performed on jugular venous blood samples that were periodically obtained a.p. and postpartum (p.p.). Health status and milk production were monitored p.p. Serum cyanocobalamin concentration increased in groups C6 and C3 p.p. Multiple daily i.v. injections of Catosal before parturition increased p.p. glucose availability, as evaluated by p.p. serum glucose concentration, and decreased peripheral fat mobilization and ketone body formation, as evaluated by p.p. serum nonesterified fatty acid and beta-OH butyrate concentrations. The number of puerperal infections in the first 5 d after calving was decreased in group C6, relative to group C0. We conclude that multiple injections of Catosal during the close-up period have a beneficial effect on the metabolism of periparturient dairy cows. Our results are consistent with the hypothesis that high-producing dairy cows in early lactation may have a relative or actual deficiency of cyanocobalamin.
Fürll
M
M
Faculty of Veterinary Medicine, University of Leipzig, 04103 Leipzig, Germany.
Deniz
A
A
Westphal
B
B
Illing
C
C
Constable
P D
PD
D020155:3-Hydroxybutyric Acid / Q000097:blood; D000818:Animals; D001663:Bilirubin / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D002417:Cattle / Q000378:metabolism*; D004032:Diet / Q000662:veterinary; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule / Q000662:veterinary; D004338:Drug Combinations; D005260:Female; D007275:Injections, Intravenous / Q000662:veterinary; D018977:Micronutrients / Q000008:administration & dosage / Q000494:pharmacology*; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D036801:Parturition / Q000378:metabolism; D010446:Peptide Fragments / Q000097:blood; D011247:Pregnancy / Q000378:metabolism; D014805:Vitamin B 12 / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology; D054311:nef Gene Products, Human Immunodeficiency Virus / Q000097:blood
D001786:Blood Glucose; D004338:Drug Combinations; C465642:HIV Nef peptide (58-68); D018977:Micronutrients; D009943:Organophosphorus Compounds; D010446:Peptide Fragments; C546561:butaphosphan, cyanocobalamin drug combination; D054311:nef Gene Products, Human Immunodeficiency Virus; D014805:Vitamin B 12; D001663:Bilirubin; D020155:3-Hydroxybutyric Acid